Trevi Therapeutics, Inc. (TRVI)

NGM – Real Time Price. Currency in USD

15.57

+0.81 (5.49%)

Market open: May 13, 2026, 2:42 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

Cost of goods sold

-132K

-147K

-123K

-43K

Gross Profit

-132K

-147K

-123K

-43K

Operating expenses (excl. COGS)

-49M

-51M

-34M

-30M

Operating Income

-49M

-52M

-34M

-30M

Non-operating income, total

719K

Pretax income

-43M

-48M

-29M

Equity in earnings

Taxes

64K

30K

32K

72K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-43M

-48M

-29M

Trevi Therapeutics, Inc. (TRVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Trevi Therapeutics, Inc. (TRVI)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Trevi Therapeutics, Inc. (TRVI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Trevi Therapeutics, Inc. (TRVI)

Income Statement (Annual)

Income Statement (Annual)